US20200368501A1 - Balloon Catheter Systems - Google Patents
Balloon Catheter Systems Download PDFInfo
- Publication number
- US20200368501A1 US20200368501A1 US16/914,178 US202016914178A US2020368501A1 US 20200368501 A1 US20200368501 A1 US 20200368501A1 US 202016914178 A US202016914178 A US 202016914178A US 2020368501 A1 US2020368501 A1 US 2020368501A1
- Authority
- US
- United States
- Prior art keywords
- balloon
- drug
- inches
- slit sleeve
- protective sleeve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 claims abstract description 160
- 239000003814 drug Substances 0.000 claims abstract description 160
- 230000001681 protective effect Effects 0.000 claims abstract description 144
- 230000023597 hemostasis Effects 0.000 claims description 57
- 239000000463 material Substances 0.000 claims description 17
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 4
- 229950009819 zotarolimus Drugs 0.000 claims description 4
- 230000010339 dilation Effects 0.000 abstract description 11
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 238000000576 coating method Methods 0.000 description 20
- 208000031481 Pathologic Constriction Diseases 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 19
- 230000002784 sclerotic effect Effects 0.000 description 19
- 208000037804 stenosis Diseases 0.000 description 19
- 208000034189 Sclerosis Diseases 0.000 description 18
- 230000036262 stenosis Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 9
- 210000005166 vasculature Anatomy 0.000 description 9
- 230000002966 stenotic effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000002930 anti-sclerotic effect Effects 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000003137 popliteal artery Anatomy 0.000 description 2
- YYUWOEMGATZTQE-XNWIYYODSA-N CCCC1C(C)[C@H](C)CC1 Chemical compound CCCC1C(C)[C@H](C)CC1 YYUWOEMGATZTQE-XNWIYYODSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920007373 Pebax® 7233 SA 01 Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1018—Balloon inflating or inflation-control devices
- A61M25/10184—Means for controlling or monitoring inflation or deflation
- A61M25/10185—Valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M2025/0098—Catheters; Hollow probes having a strain relief at the proximal end, e.g. sleeve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
- A61M2025/1004—Balloons with folds, e.g. folded or multifolded
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/107—Balloon catheters with special features or adapted for special applications having a longitudinal slit in the balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1081—Balloon catheters with special features or adapted for special applications having sheaths or the like for covering the balloon but not forming a permanent part of the balloon, e.g. retractable, dissolvable or tearable sheaths
Definitions
- Stenosis or restenosis is a narrowing of a blood vessel due to the buildup of sclerotic material. Stenosis can cause a variety of vascular conditions associated with reduced blood flow including stroke, heart disease, or limb loss.
- Drug coated balloons utilizing a variety of anti-sclerotic drugs such as Paclitaxel, Sirolimus, and/or Zotarolimus are one way of treating stenosis—the balloons are inflated to compact the sclerosis and the drugs are delivered to the vessel wall to help treat the region. Often, significant amounts of the drugs can be lost from the balloon during loading and tracking through the guiding sheath. Further, even when sufficient drug coatings are delivered to a target site, the delivery may be further hindered by the failure of the cylindrical balloon to conform to an abnormal vessel profile (e.g., non-circular) or where calcification on the vessel is particularly dense.
- an abnormal vessel profile e.g., non-circular
- a balloon catheter system that can improve drug loss from a balloon and thereby improve drug during delivery to the vessels of a patient.
- a balloon catheter that can provide improved treatment to a sclerotic region in which a typical balloon may not conform to the shape of the target region, a calcified sclerosis, or a relatively dense sclerosis.
- a protective sleeve for a drug coated balloon is described.
- the protective sleeve is useful to prevent a drug coating from rubbing off of a balloon when inserted and tracked through a guiding sheath to a target treatment site.
- the protective sleeve is configured so that the drug coated balloon can be placed within a tubular section of the protective sleeve and the protective sleeve and enclosed drug coated balloon are pushed through the guiding sheath.
- the protective sleeve includes a distal nose-cone to help prevent blood from rubbing off a drug coating from the balloon.
- the tubular section of the protective sleeve housing the drug coated balloon can be narrowed to limit the balloon's exposure to blood.
- the protective sleeve has a relatively small length, being sized to cover only the drug-coated balloon itself as it is inserted into a hemostasis valve of the guiding sheath.
- the protective sleeve is part of the balloon catheter assembly and can be removed from the balloon catheter and then placed into the hemostasis valve to aid with placing the drug coated balloon into the guiding sheath.
- a balloon catheter and balloon catheter system utilizing a protective sleeve is described.
- the protective sleeve is useful to prevent a drug coating from rubbing off of a balloon when tracked through a guiding sheath to a target treatment site.
- a balloon catheter system including a balloon catheter, utilizes a protective sleeve in which the balloon catheter is placed prior to loading the balloon catheter through a guiding sheath.
- the balloon protective sleeve and the enclosed balloon are tracked through the guiding sheath.
- the balloon catheter/balloon catheter system utilizes a distal nose cone which helps protect the balloon from blood during delivery of the balloon, where premature exposure to blood during delivery could otherwise push drug off the balloon.
- the tubular section of the protective sleeve housing the drug coated balloon can be narrowed to limit the balloon's exposure to blood.
- a balloon catheter/balloon catheter system utilizes a relatively short-length protective sleeve which is sized to aid in placing the drug coated balloon within the hemostasis valve of the guiding sheath.
- the protective sleeve can come pre-attached to the balloon catheter, in which the protective sleeve is removed from the balloon catheter and placed into the hemostasis valve to aid with placing the drug coated balloon into the guiding sheath.
- a balloon catheter has particular utility in treating stenotic regions of the vasculature which may have an irregularly shaped buildup of sclerosis, or stenotic regions with particularly thick or dense sclerosis.
- the balloon catheter utilizes a double balloon including an inner balloon and an outer balloon.
- the inner balloon is a high-pressure balloon and the outer balloon is drug-coated and highly compliant in order to conform to the stenotic vessel shape.
- a method of using a balloon catheter which includes a high-pressure inner balloon and a drug-coated, compliant outer balloon is described.
- the outer balloon is first inflated in order to conform to the stenotic vessel shape, the outer balloon delivers drugs to the sclerosis-containing vessel.
- the outer balloon is then deflated.
- the high-pressure inner balloon is then inflated in order to compress the sclerosis so that a relatively consistent lumen is formed within the vessel.
- FIG. 1 a illustrates a typical drug-coated balloon which is part of a balloon catheter.
- FIG. 1 b illustrates a balloon protective sleeve according to one embodiment.
- FIG. 1 c illustrates the drug-coated balloon of FIG. 1 a within the protective sleeve of FIG. 1 b.
- FIG. 2 illustrates the balloon protective sleeve of FIG. 1 within a larger guiding sheath.
- FIG. 3 a illustrates the distal end of the balloon protective sleeve of FIG. 1 .
- FIG. 3 b illustrates a proximal cut-out section of the balloon protective sleeve of FIG. 1 .
- FIG. 4 illustrates a balloon within a balloon protective sleeve.
- FIG. 6 illustrates a balloon protective sleeve utilizing a distal nose cone.
- FIG. 7 illustrates a side view of a balloon protective sleeve with a narrow distal section.
- FIG. 8 illustrates another view of the balloon protective sleeve of FIG. 7 .
- FIG. 9 illustrates a shortened balloon protective sleeve used solely to track the drug coated balloon through a hemostasis valve of a guiding sheath.
- FIG. 10 illustrates the shortened balloon protective sleeve of FIG. 9 pre-mounted to a proximal region of a balloon catheter.
- FIG. 11 illustrates a drug coated balloon prior to being inserted into the shortened balloon protective sleeve of FIG. 9 .
- FIG. 12 illustrates a drug coated balloon being placed into the shortened balloon protective sleeve of FIG. 9 .
- FIG. 13 illustrates a drug coated balloon with the shortened balloon protective sleeve of FIG. 9 being placed into the hemostasis valve of a guiding sheath.
- FIG. 14 illustrates a stenosis site within the vasculature.
- FIG. 15 illustrates a balloon catheter utilizing an inner and an outer balloon that can be used to treat the stenosis site of FIG. 14 .
- Drug-coated balloons are used for a variety of vascular conditions, including stenosis—which is a condition where sclerotic material builds up in the blood vessels, affecting the normal circulation of blood through the vasculature. Restenosis is the continued occurrence of stenosis where treatment to treat the sclerosis is unsuccessful and results in the continued existence and buildup of sclerotic material within the vasculature.
- stenosis which is a condition where sclerotic material builds up in the blood vessels, affecting the normal circulation of blood through the vasculature.
- Restenosis is the continued occurrence of stenosis where treatment to treat the sclerosis is unsuccessful and results in the continued existence and buildup of sclerotic material within the vasculature.
- a drug coated balloon can be used in several target areas, including for treatment of stenosis in the superficial femoral or popliteal arteries which are larger arteries in the legs.
- this procedure involves a balloon catheter having a drug coated balloon on its distal end.
- Various anti-sclerotic drugs can be coated onto the balloon, such as Paclitaxel, Sirolimus, and/or Zotarolimus.
- the balloon is tracked through a larger guiding sheath to the target treatment site.
- the balloon is then delivered and inflated at the stenosis site to compress the sclerotic material and deliver drug to the vessel wall to prevent the future buildup of sclerotic material.
- One complication with delivery of drug coated balloons is that the drug coating can rub off the balloon. This can occur primarily in two scenarios—first, when the drug coated balloon is initially placed through the hemostasis valve of the guiding sheath for entry into the guiding sheath (where most of the drug loss typically takes place). Second, when the drug coated balloon is being pushed through the guiding sheath. This drug loss is due to contact friction between the balloon and, respectively, the hemostasis valve and the inner surface of the guiding sheath. Drug loss during placement and tracking can limit the amount of drug that is available to treat the stenosis and can enhance the chance of continued stenosis or restenosis since less drug is available to treat the problem region.
- Embodiments herein include protective sleeves designed to help protect the drug coated balloon during placement within the hemostasis valve of the guiding sheath as well as during tracking through the larger guiding sheath.
- protective sleeves designed to help protect the drug coated balloon during placement within the hemostasis valve of the guiding sheath as well as during tracking through the larger guiding sheath.
- FIG. 1 a shows a typical drug-coated balloon catheter 103 having an inflatable drug-coated balloon 102 mounted on the distal end of the catheter 103 and in which a portion of the balloon has a drug coating 102 A.
- substantially all of the length and circumference of the balloon 102 includes the drug coating 102 A.
- the proximal and distal tapered ends of the balloon 102 are free of the drug coating, since these portions are unlikely to contact the vessel.
- the drug-coated balloon catheter 103 includes an elongated body portion 106 having a first lumen 106 A located along all or a portion of the length of the body portion 106 and through which a guidewire 108 can be advanced (and/or a contrast agent or therapeutic material can be delivered within the patient).
- a second inflation lumen 106 B extends from a proximal end of the body portion 106 to an opening within the balloon 102 , allowing for delivery of inflation media during a procedure.
- Balloon catheters also often include a separate rapid exchange port 106 C at some distal location along the body portion 106 and lumen 106 A to allow quicker placement and removal of the guidewire 108 , as shown in FIG. 1 a .
- Balloon catheters 103 are typically placed into a hemostasis valve of a guiding sheath and then are delivered through the guiding sheath for delivery to a target treatment area, however, as discussed above, there is significant drug loss associated with these steps.
- FIG. 1 b illustrates a protective sleeve 100 according to one embodiment to protect the drug-coated balloon 102 of the drug-coated balloon catheter 103 during placement through the hemostasis valve of the guiding sheath and passage through the guiding sheath.
- the protective sleeve 100 includes a distal tubular section 101 and a proximal body portion 105 having an arc-shaped channel or “half-pipe” shaped region 105 A that extends to the proximal end of the body portion 105 that forms an opening 104 to the distal tubular section 101 .
- the balloon 102 is advanced within the distal tubular section 101 , since both the proximal aperture 104 and internal diameter of the section 101 are larger than the deflated diameter of the balloon 102 .
- the body portion 106 of the catheter 103 can be positioned within the non-tubular arc-shaped region 105 A.
- the protective sleeve 100 is placed over the catheter 103 , with the balloon already inside of the distal tubular section 101 prior to placement within the hemostasis valve 112 of guiding sheath 110 and is then pushed through guiding sheath 110 —as shown in FIG. 2 .
- Protective sleeve 100 provides an intermediate surface to protect the balloon from direct contact with the hemostasis valve 112 when the drug-coated balloon 102 enters the guiding sheath 110 , as well as an intermediate surface to protect the drug-coated balloon 102 from direct contact with the inner diameter of the guiding sheath when tracked through said guiding sheath 110 .
- Drug loss primarily occurs during placement through the hemostasis valve 112 (due to the reduced diameter of the hemostasis valve, as well as the rough texture of the hemostasis valve) and secondarily during tracking through the guiding sheath 110 .
- the protective sleeve 100 reduces or eliminates these problems by protecting the drug-coated balloon 102 when it enters the hemostasis valve 112 and during tracking through the guiding sheath 110 .
- the protective sleeve 100 should be sized to fit within the inner diameter of the guiding sheath 110 so it can be advanced through the guiding sheath 110 .
- the external surface of the balloon protective sleeve 100 can utilize a hydrophilic or other friction-reducing coating to reduce friction with the external guiding sheath 110 .
- the balloon protective sleeve 100 may also be made of a lubricious polymer to reduce friction between the overlying guiding sheath 110 and underlying protective sleeve 100 .
- the protective sleeve 100 is advanced by the physician at its proximal end to so as to also advance the enclosed balloon catheter 103 through guiding sheath 110 .
- the proximal section 105 of the protective sleeve 100 is not a fully enclosed tube like distal section 101 , but rather an arc-shaped or “half-pipe” shaped region 105 A. This configuration increases the ease of loading the drug coated balloon 102 since the balloon 102 must only be pushed through cut-out aperture 104 to access the distal tubular section 101 instead of being pushed through the entire length of the balloon protective sleeve 100 , which would be the case if the entire length of the balloon protective sleeve 100 had a completely enclosed tubular shape.
- the physician can advance both the sleeve 100 and the catheter 103 together by manipulating only the proximal end of the proximal body portion 105 (or optionally both proximal ends of the proximal body portion 105 and the catheter 103 ).
- the proximal body portion 105 can be thought of as a navigational section since a user grips the proximal part of proximal body portion 105 to move protective sleeve 100 along with the enclosed balloon catheter 103 and drug coated balloon 102 .
- the drug coated balloon 102 is exposed in one of a few ways.
- the protective sleeve 100 is pushed out from the guiding sheath 110 or the guiding sheath 110 is proximally withdrawn to expose the distal tubular section 101 of protective sleeve 100 .
- the protective sleeve 100 is retracted to expose drug coated balloon 102 , the balloon catheter is pushed out from the protective sleeve 100 , or both techniques can be performed together (in a dual push/pull method).
- the drug-coated balloon 102 is located within the protective sleeve 100 , a small amount of drug loss due to friction between the drug-coated balloon 102 and the protective sleeve 100 may be possible, however this drug loss is much less than the amount that would otherwise occur without the sleeve 100 .
- the inner surface of protective sleeve 100 may include a hydrophilic or otherwise friction-reducing coating, or be made of a lubricious polymer.
- the distal end of the distal tubular section 101 may further include a radiopaque (e.g. tantalum) marker band 114 , as seen in FIG. 3 a .
- Guiding sheaths 110 often include a marker band at about 3 cm from the distal tip so that a device delivered through the guiding sheath can be aligned with the distal tip to ensure proper placement relative to the guiding sheath 110 .
- the marker band 114 when aligned with the marker band of guiding sheath 110 , helps the user ascertain that the protective sleeve is at the distal end of the guiding sheath.
- the aperture 104 created between the distal tubular region 101 and the channel 105 A can be formed from a generally perpendicular wall cut (i.e., a cut perpendicular to the elongated axis of the sleeve 100 , as seen in FIG. 1 b , or can be cut at an angle that decreases in the proximal direction, as seen in FIG. 3 b (e.g., 45 degrees or an angle less than 90 degrees) to create a transition between the two regions 101 , 105 A.
- a generally perpendicular wall cut i.e., a cut perpendicular to the elongated axis of the sleeve 100 , as seen in FIG. 1 b
- an angle that decreases in the proximal direction as seen in FIG. 3 b (e.g., 45 degrees or an angle less than 90 degrees) to create a transition between the two regions 101 , 105 A.
- the protective sleeve 100 can be manufactured by cutting a portion of a tube between the aperture 104 and the proximal end of the proximal section 105 , thereby forming the arc-shaped or channel portion 105 A.
- a distal tubular section 101 can be connected to an entire tube cut lengthwise to form the proximal portion 105 .
- Drug coated balloons are often pleated, as shown in FIG. 4 , to reduce the amount of drug that can potentially be lost.
- the pleat 116 includes an outer region 116 A which may contact the surface overlying the balloon 102 and an inner region 116 B which is protected from the overlying surface. This pleated design helps ensure the entire surface of the balloon is not exposed and thereby limits the amount of drug that is lost during placement and tracking.
- the drug coated balloon 102 includes a lumen 106 A that accommodates a guidewire 108 , shown in FIG. 1A , and provides a path for any subsequently introduced therapeutic materials that may be used in the treatment area.
- the proximal end of balloon 102 is connected to an inflation lumen 1066 to allow inflation media (e.g. liquid contrast agent) to be injected through a port in the catheter body 106 to inflate the balloon 102 once deployed in the target treatment site in the vasculature.
- inflation media e.g. liquid contrast agent
- FIG. 5 shows the balloon and balloon protective sleeve 100 being placed within the hemostasis valve 112 of guiding sheath 110 , for tracking through said guiding sheath 110 .
- the balloon 102 is preplaced within distal tubular section 101 of protective sleeve 100 and sold as a package to the end user.
- the end user physically places the balloon 102 within distal tubular section 101 of protective sleeve 100 , for example by pushing the balloon 102 through aperture 104 of protective sleeve 100 .
- the protective sleeve 100 is physically placed within the hemostasis valve 112 and pushed through guiding sheath 110 in the manner described earlier.
- the balloon 102 may need to be placed within a temporary protective structure to prevent drug loss during the storage and shipping process—this temporary protective structure would then be removed by the end user when said user places the balloon within the distal tubular section 101 of protective sleeve 100 .
- the protective sleeve 100 can forego cut-out region 105 A and instead is entirely tubular. With this embodiment, it would be beneficial for the protective sleeve 100 to be sold/delivered pre-loaded with the drug coated balloon 102 to the end-user to minimize the effort needed to track the balloon through a fully tubular protective structure.
- the earlier discussion highlighted placement of a drug-coated balloon 102 within a guiding sheath 110 , as well as tracking the balloon 102 through the guiding sheath 110 , as the primary scenarios where drug loss can occur.
- exposure to blood can also cause drug loss from the drug coated balloon 102 .
- the distal part of the drug-coated balloon 102 may contact blood even before the balloon 102 is deployed, and the pressurized flow of blood may cause of the drug coating 102 A to be removed from the balloon 102 .
- the protective sleeve 100 can address some of these issues by limiting the amount of balloon surface which the blood can contact due to the surface area of the protective sleeve 100 .
- the protective sleeve 100 alone may not entirely prevent drug loss due to blood contact.
- FIGS. 6-8 describe various embodiments to reduce this drug loss due to blood contact/blood flow.
- a nose cone 118 is attached to the distal end of catheter body 106 , past the distal end of balloon 102 that helps block or redirect direct blood flow contact with the balloon 102 , thereby further reducing loss of the drug coating 102 A.
- the nose cone 118 is either disposed around the catheter body 106 or includes a passage through it that is aligned with the lumen 106 A, such that the nose cone 118 provides an outlet for a guidewire or other agents advanced through the lumen 106 A.
- the nose cone 118 can be a proximally-increasing conical shape as pictured or similar ramped shape so that the proximal end of the cone has the greatest thickness to prevent blood from prematurely contacting the balloon during delivery, while the distal end has a smaller profile in order to not materially impede blood flow once the balloon is placed within the vasculature.
- a variety of shapes are contemplated including cones, cylinders, elliptical, ovular, and/or bullet-like shapes.
- the nose cone 118 is located within the balloon protective sleeve 110 and the proximal end of the nose cone 118 has a diameter similar to the inner diameter of the balloon protective sleeve 100 , thereby preventing blood from contacting the drug-coated balloon 102 .
- the nose cone 118 is located distal to balloon protective sleeve 110 and the proximal end of nose cone 118 is has a diameter similar to the inner diameter of guiding sheath 110 .
- FIGS. 7-8 illustrate one such embodiment, in which a balloon protective sleeve 200 has a diametrically narrowed distal section 220 relative to the proximal portion of the distal tubular section 201 .
- the narrowed distal section 220 accommodates all of the balloon 102 or solely the distal part of the balloon as the balloon 102 is being housed within the protective sleeve while tracking through the guiding sheath 110 .
- Narrowed distal section 220 has a smaller diameter compared to the rest of the distal tubular section 201 (which accommodates the balloon 102 ) of protective sleeve 200 and therefore sits tighter relative to the balloon, limiting the space for blood to enter. This mitigates the chance that blood can enter and remove the drug coating 102 A from the balloon 102 .
- Narrowed distal section 220 shown in FIGS. 7-8 can be used instead of the nose cone 118 shown in FIG. 6 , or can be used along with nose-cone 118 to provide multiple levels of protection to help prevent blood from pushing or washing the drug coating 102 A off of the balloon.
- the entire section that the drug-coated balloon 102 is located within can be relatively narrow.
- just a distal part is narrowed such that a proximal section of the balloon 102 is located in an enlarged proximal section while the distal section of the balloon is located within a narrowed section 220 .
- An alternative embodiment utilizing the narrowed distal section 220 described above can utilize a fuller distal section that the balloon sits within (sized similar to tubular section 101 in FIGS. 1-2 ), then a smaller narrowed distal section 220 beyond this balloon, where the narrowed section would limit the amount of blood that could enter the protective sleeve and contact the drug coated balloon 102 .
- the proximal section 105 of the protective sleeve 100 is not tubular in several of the embodiments to ease placement of the drug coated balloon 102 within the protective sleeve 100 .
- one drawback to this arrangement is that since the proximal part 105 of the protective sleeve 100 is cut-away to form a channel 105 A, there is less axial strength or kink resistance to the protective sleeve 100 due to the smaller cross-sectional area.
- the proximal section 205 of the protective sleeve has a greater curvature to the arc of its channel 205 A compared to the channel 105 A shown in the embodiment of FIGS. 1-3 b , which is accomplished by making a more scalloped cut at region 204 (i.e., a cut of increased circumference/width) to define the entry point for the drug coated balloon.
- This scalloped cut is defined by a divot or inward tapered cut region 204 a which creates enough of a gap, entry, space, or port to accommodate the drug coated balloon 102 within the distally placed tubular section 201 , which may not otherwise fit due to the relatively narrow channel 105 A opening.
- This proximal section 105 with a smaller opening of the channel 205 A may be used in any of the protective sleeve embodiments to augment the push strength of the protective sleeve.
- the primary locations in which loss of the drug coating can occur when tracking a drug coated balloon through a guiding sheath, as discussed earlier, are during placement within a hemostasis valve 112 of a guiding sheath 110 as well as during tracking through the guiding sheath 110 —where the hemostasis valve 112 is the location where the greatest amount of drug coating 102 A is lost. Loss of drug coating 102 A occurs due during placement through the hemostasis valve 112 for a few reasons. First, the smaller diameter of the hemostasis valve 112 compared to the guiding sheath diameter causes increased contact friction with the balloon 102 when the balloon 102 is placed through the hemostasis valve 112 .
- the hemostasis valve port is not smooth which can promote loss of drug coating 102 A due to friction.
- drug-coated balloons 102 are fairly soft, meaning the physician generally must grip the balloon 102 to propel it through the hemostasis valve 112 , which causes loss of the drug coating due to touch.
- retrograde blood flow through the hemostasis valve 112 can also cause drug loss due to contact with blood.
- the following embodiments are directed to a relatively shorter protective sleeve that functions solely to protect the drug coated balloon 102 when its inserted into the hemostasis valve 112 —which is the primary scenario where blood loss occurs, but does necessarily not protect the balloon 102 while it is tracked through the guiding sheath 110 .
- FIG. 9 illustrates a shortened protective sleeve 300 which can also be considered an insertion sleeve 300 since the function of the sleeve is to protect the drug-coated balloon 102 solely during insertion through the hemostasis valve 112 of a guiding sheath 110 . Since protective sleeve 300 only protects the balloon during insertion into the hemostasis valve 112 it can be much shorter than protective sleeve embodiments 100 and 200 in FIGS. 1-8 which must span the complete length of the guiding sheath 110 .
- the protective sleeve 300 can be placed over the balloon 102 when the balloon 102 is placed inside the hemostasis valve 112 of guiding sheath 110 to protect the drug-coated balloon from drug loss when being placed within said hemostasis valve 112 .
- the protective sleeve 300 has a thin cut 301 extending along its entire length (e.g. a cut 301 a defining an opening that is 0.002 inches or less), forming a cross-sectional c-shape instead of a completely oval/circular shape.
- One end of protective sleeve 300 is preferably flared or radially opened to form a flared end 305 (i.e., the cut 301 A increases in width in the proximal direction).
- the protective sleeve 300 is formed as a cylinder but the cut 301 A in section 305 is larger than cut 301 in the rest of the sleeve causing flared end 305 to adopt its flared shape—meaning the larger shape of the flared end is due to the larger cut used in region 305 .
- cut 301 A is tapered such that the cut size in end section 301 C is larger than the cut size in section 301 B.
- the cut-size in end section 301 C defines an opening of about 0.17 inches to about 0.23 inches.
- the protective sleeve 300 is about 2.75-3.25 inches in length and the flared end is about 0.5 to 1 inch in length.
- protective sleeve 300 is about 3 inches, about 7.62 centimeters, or about 8 centimeters in length and flared end 305 is about 0.75 inches in length.
- Protective sleeve 300 can be formed from a variety of materials including a polymeric material such as Pebax 7233 SA01.
- protective sleeve 300 has an inner diameter of about 0.1 inches and an outer diameter of about 0.115 inches. Since protective sleeve 300 is generally formed from a cylinder which is given a larger cut in region 301 C to adopt the flared end 305 as described earlier, the protective sleeve diameter can be thought of as the outer diameter of the sleeve plus the size of the cut.
- the protective sleeve's flared end 305 diameter is about 0.285 inches to 0.345 inches, or about 0.315 inches—while the protective sleeve's diameter in the non-flared portion of the sleeve is about 0.115 inches to 0.12 inches, or about 0.117 inches.
- FIG. 10 shows an embodiment in which the protective sleeve 300 is pre-placed on the proximal part of the balloon catheter 103 , where the balloon catheter 100 is sold to the end user with the protective sleeve 300 already located on the proximal part of said balloon catheter 100 .
- the proximal end of protective sleeve 300 (which coincides with flared end 305 ) would sit over the enlarged strain relief 303 of the balloon catheter 103 .
- Proximal flare 305 is useful for a couple purposes.
- the flare provides a slightly enlarged region to better fit over strain relief 303 .
- the proximal flare 305 provides a smoother entry for the drug coated balloon when said balloon is loaded through said protective sleeve 300 . Comparing FIG. 9 and FIG. 10 , cut 301 would sit on the bottom of protective sleeve 300 shown in FIG. 10 . The user can simply remove protective sleeve 300 from the balloon catheter 103 , and then place the protective sleeve 300 within the hemostasis valve of the guiding sheath—in a manner that will be explained in more detail below.
- FIGS. 11-13 The method of using protective sleeve 300 is shown in FIGS. 11-13 . Please note, as pertains to the figures anything on the left side would be considered distal and anything on the right side would be considered proximal.
- Protective sleeve 300 is first removed from the proximal section of balloon catheter 103 so that the distal section of said balloon catheter 103 is later be placed through said protective sleeve 300 . Due to the presence of the cut 301 , this removal can occur by applying force against the cut 301 (referring to FIG. 10 , one pulls upwards to remove sleeve 300 since cut 301 is located on the bottom of the sleeve 300 ).
- drug coated balloons come pre-shipped in a protective tube 307 during shipping and handling to protect the drug after manufacture.
- This protective tube 307 must be removed prior to using the drug coated balloon/balloon catheter, prior to placement within the hemostasis valve of the guiding sheath.
- the distal part of the balloon catheter, which includes the drug coated balloon which is located at the distal end of the balloon catheter 103 around balloon catheter lumen 103 is shown in FIG. 11 .
- the distal part of the balloon catheter including surrounding protective tube 307 is inserted through the protective sleeve 300 , so that the distal part of the balloon catheter and distal part of protective tube 307 sits past the distal end of protective sleeve 300 .
- Protective tube 307 is then pulled distally (to the left) as shown in FIG. 12 to remove the protective tube 300 from the balloon 102 .
- the protective sleeve 300 is then placed within the hemostasis valve 112 of guiding sheath 110 so that the protective sleeve 300 is positioned through the entire hemostasis valve 112 .
- the balloon catheter is then pushed distally (in a leftward direction) to propel the balloon 102 through the hemostasis valve 112 and into the guiding sheath 110 .
- the protective sleeve 300 is proximally retracted (pulled to the right) and removed (e.g. by pulling against the cut, so pulling upwards in FIG. 13 to remove the entire sleeve 300 ) and the rest of the balloon catheter 103 is pushed through the hemostasis valve 112 and into the guiding sheath 110 .
- Alternative embodiments have a shortened protective sleeve 300 as a separate element that is unconnected to balloon catheter 103 ; however pre-placement on balloon catheter 103 would provide a more convenient format to locate the shortened protective sleeve 300 as part of a balloon catheter system or kit.
- Alternative embodiments may also utilize a pre-scored or pre-weakened region in place of cut 301 , in which the user applies enough pressure to tear open region 301 .
- insertion sleeve/protective sleeve 300 protects the drug coated balloon 102 from contact with the reduced diameter and roughened area of the hemostasis valve 112 , thus mitigating the issue of drug loss during placement through said hemostasis valve 112 .
- One additional advantage of the cut section 301 of the protective sleeve 300 is that when the sleeve is placed into a small-diameter tube, the ends of the tube can overlap to fit the smaller profile.
- the protective sleeve 300 can curl over itself to fit this reduced diameter (meaning the protective sleeve 300 can conform to fit a much smaller diameter hemostasis valve—by contrast, a non-cut tube could not fit into a hemostasis valve with a smaller diameter than the tube for obvious reasons).
- the earlier description discussed one cause of drug loss being exposure to blood.
- the ability of the protective sleeve 300 to contract to fit the hemostasis valve 300 means there is less exposed surface area of the drug coated balloon available exposed to blood, further minimizing the chance of drug falling off the balloon during placement.
- the sleeves In the protective sleeve embodiments of FIGS. 1-8 in which the protective sleeve extends the length of the guiding sheath and includes a distal tubular section to support the drug coated balloon, the sleeves must be relatively long since they are positioned within the guiding sheath 110 .
- the distal tubular sections 101 , 201 must also be sized similar to the length of the drug coated balloons. Drug coated balloons 102 can be anywhere from 40-200 millimeters in length depending on the size of the vascular area treated, so the distal tubular sections 101 , 201 must be at least this size to accommodate the balloon.
- the insertion sleeve/protective sleeve 300 is that it is relatively short since it only must be large enough to span hemostasis valve 112 of the guiding sheath.
- the protective sleeve 300 is about 3 inches, 7.62 centimeters, or about 8 centimeters in length.
- sclerotic material builds up in a vessel, it often adopts awkward shapes—as shown in the vessel cross section shown in FIG. 14 in which vessel 400 has sclerotic material 402 which leaves a smaller vessel cross section 404 for blood flow.
- the sclerotic buildup narrows the space that blood can flow through the vessel, diminishing blood flow through the vessel in a phenomenon called stenosis—which can cause a variety of complications.
- Typical treatment procedures can proceed in a couple ways.
- One treatment option uses a high-pressure balloon to inflate and compress the sclerosis to try to restore regular blood flow to the vessel.
- the sclerosis is particularly dense or if stenosis keeps recurring (a phenomenon known as restenosis), this method is not useful.
- a second treatment option is to use a drug-coated balloon to apply drug to the vessel wall and sclerotic material to try to treat the stenosis.
- the irregular profile of the sclerotic material can make it difficult to effectively apply the drug equally around the vessel since it would be difficult for the balloon to adopt the awkward shape to conform to vessel cross-section 404 —in fact, inserting a drug coated balloon by itself would result in the drug-coated balloon only touching the “narrowest” part of the sclerotic region which is a very inefficient way to deliver the drugs. Additionally, the presence of a thick sclerotic layer would make it difficult for the drug to reach the wall of the blood vessel.
- a pre-dilation step to address this problem, where a first high-pressure balloon is inserted into the sclerotic region and expanded in order to compress the sclerosis and produce a consistent circular lumen—once there is a consistent circular lumen, it is much easier for the drug coated balloon to adopt a circular shape to treat the area.
- a second balloon a drug coated balloon which can be coated with anti-sclerotic drug such as Paclitaxel, Sirolimus, and/or Zotarolimus is then inserted and inflated to contact the sclerosis and vessel wall, and deliver drugs to said sclerosis and tissue.
- This procedure can take a substantial amount of time since a first balloon must be tracked through a guiding sheath and delivered to the target site and inflated for the pre-dilation step and then be deflated and withdrawn through the guiding sheath. Then a drug-coated balloon must be tracked through the guiding sheath and placed at the target site, expanded to deliver the drug, and then removed and withdrawn.
- the extra-step of pre-dilation takes extra time and can increase the risk of complications such as stroke in circumstances where there is significant narrowing of the blood vessels due to sclerosis.
- the following embodiments deal with a dual-balloon microcatheter system which includes both a dilation balloon and a compliant drug-coated balloon so that the dilation and drug delivery can take place simultaneously.
- FIG. 15 illustrates a balloon catheter system 405 having two balloons.
- the two-balloon system utilizes an outer, primary, highly-compliant drug coated balloon 406 and an inner, secondary, high-pressure balloon 408 .
- the inclusion of two balloons on one balloon catheter eliminates the need for a separate pre-dilation step since the inner balloon can dilate the vessel while the outer balloon can then conform to the stenosis after dilation and therefore there is no need for two separate balloon catheters and the time associated with tracking two separate balloon catheters through the vasculature to treat the stenosis.
- the two balloons are concentric, as is shown in FIG. 15 .
- the balloon catheter contains two inflation lumens, one ( 408 a ) to inflate the inner balloon and the other ( 408 b ) to inflate the outer balloon—while a third lumen 410 provides access for a guidewire or additional therapeutic materials.
- Typical inflation media such as liquid contrast agent can be used to inflate the balloons.
- the inner balloon is a high-pressure balloon and should be high strength in order compress the sclerosis, thereby dilating the vessel.
- Conventional high-pressure balloon material such as nylon can be used for this inner/secondary balloon 408 .
- the outer balloon 406 is highly conformable and is meant to conform to the shape of the sclerotic region in order to ensure even drug delivery throughout the entire sclerotic region.
- Soft, compliant material is therefore ideal for the inner/primary balloon;
- Polyblend 18-45 may be used for the inner/primary balloon.
- the method of use of the dual-balloon catheter system 406 to treat a sclerotic region like the one shown in FIG. 14 is described, as follows.
- the primary, compliant outer drug-coated balloon 406 is first inflated and due to the compliant nature of the balloon, this balloon can generally conform to the shape of the sclerotic region to deliver drug to the region—however depending on the nature of the stenotic shape it may not completely comply with the shape if the shape is particularly complex or irregular.
- the physician can observe the treatment site through fluoroscopy to determine how well the compliant, drug-coated balloon conforms to the vessel shape.
- the primary, outer balloon 406 is deflated and the secondary, inner high-pressure balloon 408 is then inflated. Since the outer balloon 406 is located over the inner balloon 408 , the outer balloon 406 maintains contact with the sclerosis, but the force from the inner-high pressure balloon further compresses the sclerosis and creates a consistent, open lumen for blood flow through the vessel.
- outer drug-coated balloon 406 is complying to the stenosis shape, it may still be desirable to use a dilation procedure to decrease the amount of stenosis buildup and “open” up the vessel for blood flow—the inclusion of the high pressure inner balloon 408 allows this to be done while utilizing the same balloon catheter.
- a dual lumen inflation system can be used with two balloons where the balloons are positioned longitudinally adjacent with respect to each other (i.e., proximally/distally of each other).
- One balloon is a compliant drug-coated balloon
- a second linearly displaced balloon is a high-pressure balloon.
- the balloons can be used in either order (e.g. either the compliant, drug-coated balloon or the high-pressure balloon could be inflated and used first).
- the catheter can be linearly moved so that either the first balloon or the second balloon is aligned with the sclerotic region.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A balloon catheter and balloon system particularly useful with drug-coated balloons is described. In some embodiments, the balloon catheter system includes various features designed to address problems with drug rubbing off due to contract friction during delivery of the balloon—including by utilizing a protective sleeve to shield the drug-coated balloon. In some embodiments, the balloon catheter system includes an inner high-pressure balloon and an outer drug-coated balloon to mitigate the time associated with performing vessel dilation.
Description
- This application is a continuation and claims priority to U.S. patent application Ser. No. 15/726,264 filed Oct. 5, 2017 entitled Balloon Catheter Systems, which claims benefit of and priority to U.S. Provisional Application Ser. No. 62/404,647 filed Oct. 5, 2016 entitled Balloon Catheter Systems, and to U.S. Provisional Application Ser. No. 62/414,520 filed Oct. 28, 2016 entitled Balloon Catheter Systems, all of which are hereby incorporated herein by reference in their entireties.
- Stenosis or restenosis is a narrowing of a blood vessel due to the buildup of sclerotic material. Stenosis can cause a variety of vascular conditions associated with reduced blood flow including stroke, heart disease, or limb loss. Drug coated balloons utilizing a variety of anti-sclerotic drugs such as Paclitaxel, Sirolimus, and/or Zotarolimus are one way of treating stenosis—the balloons are inflated to compact the sclerosis and the drugs are delivered to the vessel wall to help treat the region. Often, significant amounts of the drugs can be lost from the balloon during loading and tracking through the guiding sheath. Further, even when sufficient drug coatings are delivered to a target site, the delivery may be further hindered by the failure of the cylindrical balloon to conform to an abnormal vessel profile (e.g., non-circular) or where calcification on the vessel is particularly dense.
- In this regard, there is a need for a balloon catheter system that can improve drug loss from a balloon and thereby improve drug during delivery to the vessels of a patient. There is also a need for a balloon catheter that can provide improved treatment to a sclerotic region in which a typical balloon may not conform to the shape of the target region, a calcified sclerosis, or a relatively dense sclerosis.
- In some embodiments, a protective sleeve for a drug coated balloon is described. The protective sleeve is useful to prevent a drug coating from rubbing off of a balloon when inserted and tracked through a guiding sheath to a target treatment site.
- In one embodiment, the protective sleeve is configured so that the drug coated balloon can be placed within a tubular section of the protective sleeve and the protective sleeve and enclosed drug coated balloon are pushed through the guiding sheath. In one embodiment, the protective sleeve includes a distal nose-cone to help prevent blood from rubbing off a drug coating from the balloon. In one embodiment, the tubular section of the protective sleeve housing the drug coated balloon can be narrowed to limit the balloon's exposure to blood.
- In one embodiment, the protective sleeve has a relatively small length, being sized to cover only the drug-coated balloon itself as it is inserted into a hemostasis valve of the guiding sheath. In one embodiment, the protective sleeve is part of the balloon catheter assembly and can be removed from the balloon catheter and then placed into the hemostasis valve to aid with placing the drug coated balloon into the guiding sheath.
- In some embodiments, a balloon catheter and balloon catheter system utilizing a protective sleeve is described. The protective sleeve is useful to prevent a drug coating from rubbing off of a balloon when tracked through a guiding sheath to a target treatment site.
- In one embodiment, a balloon catheter system, including a balloon catheter, utilizes a protective sleeve in which the balloon catheter is placed prior to loading the balloon catheter through a guiding sheath. The balloon protective sleeve and the enclosed balloon are tracked through the guiding sheath. In one embodiment, the balloon catheter/balloon catheter system utilizes a distal nose cone which helps protect the balloon from blood during delivery of the balloon, where premature exposure to blood during delivery could otherwise push drug off the balloon. In one embodiment, the tubular section of the protective sleeve housing the drug coated balloon can be narrowed to limit the balloon's exposure to blood.
- In one embodiment, a balloon catheter/balloon catheter system utilizes a relatively short-length protective sleeve which is sized to aid in placing the drug coated balloon within the hemostasis valve of the guiding sheath. In some embodiments, the protective sleeve can come pre-attached to the balloon catheter, in which the protective sleeve is removed from the balloon catheter and placed into the hemostasis valve to aid with placing the drug coated balloon into the guiding sheath.
- In some embodiments, a balloon catheter is described. The balloon catheter has particular utility in treating stenotic regions of the vasculature which may have an irregularly shaped buildup of sclerosis, or stenotic regions with particularly thick or dense sclerosis.
- In one embodiment, the balloon catheter utilizes a double balloon including an inner balloon and an outer balloon. The inner balloon is a high-pressure balloon and the outer balloon is drug-coated and highly compliant in order to conform to the stenotic vessel shape.
- In one embodiment, a method of using a balloon catheter which includes a high-pressure inner balloon and a drug-coated, compliant outer balloon is described. The outer balloon is first inflated in order to conform to the stenotic vessel shape, the outer balloon delivers drugs to the sclerosis-containing vessel. The outer balloon is then deflated. The high-pressure inner balloon is then inflated in order to compress the sclerosis so that a relatively consistent lumen is formed within the vessel.
- These and other aspects, features and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which:
-
FIG. 1a illustrates a typical drug-coated balloon which is part of a balloon catheter. -
FIG. 1b illustrates a balloon protective sleeve according to one embodiment. -
FIG. 1c illustrates the drug-coated balloon ofFIG. 1a within the protective sleeve ofFIG. 1 b. -
FIG. 2 illustrates the balloon protective sleeve ofFIG. 1 within a larger guiding sheath. -
FIG. 3a illustrates the distal end of the balloon protective sleeve ofFIG. 1 . -
FIG. 3b illustrates a proximal cut-out section of the balloon protective sleeve ofFIG. 1 . -
FIG. 4 illustrates a balloon within a balloon protective sleeve. -
FIG. 5 illustrates the balloon protective sleeve ofFIG. 1 being placed within a hemostasis valve of a guiding sheath. -
FIG. 6 illustrates a balloon protective sleeve utilizing a distal nose cone. -
FIG. 7 illustrates a side view of a balloon protective sleeve with a narrow distal section. -
FIG. 8 illustrates another view of the balloon protective sleeve ofFIG. 7 . -
FIG. 9 illustrates a shortened balloon protective sleeve used solely to track the drug coated balloon through a hemostasis valve of a guiding sheath. -
FIG. 10 illustrates the shortened balloon protective sleeve ofFIG. 9 pre-mounted to a proximal region of a balloon catheter. -
FIG. 11 illustrates a drug coated balloon prior to being inserted into the shortened balloon protective sleeve ofFIG. 9 . -
FIG. 12 illustrates a drug coated balloon being placed into the shortened balloon protective sleeve ofFIG. 9 . -
FIG. 13 illustrates a drug coated balloon with the shortened balloon protective sleeve ofFIG. 9 being placed into the hemostasis valve of a guiding sheath. -
FIG. 14 illustrates a stenosis site within the vasculature. -
FIG. 15 illustrates a balloon catheter utilizing an inner and an outer balloon that can be used to treat the stenosis site ofFIG. 14 . - Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.
- Drug-coated balloons are used for a variety of vascular conditions, including stenosis—which is a condition where sclerotic material builds up in the blood vessels, affecting the normal circulation of blood through the vasculature. Restenosis is the continued occurrence of stenosis where treatment to treat the sclerosis is unsuccessful and results in the continued existence and buildup of sclerotic material within the vasculature.
- One method of treating stenosis is the use of a drug coated balloon. These drug coated balloons can be used in several target areas, including for treatment of stenosis in the superficial femoral or popliteal arteries which are larger arteries in the legs. Typically, this procedure involves a balloon catheter having a drug coated balloon on its distal end. Various anti-sclerotic drugs can be coated onto the balloon, such as Paclitaxel, Sirolimus, and/or Zotarolimus. The balloon is tracked through a larger guiding sheath to the target treatment site. The balloon is then delivered and inflated at the stenosis site to compress the sclerotic material and deliver drug to the vessel wall to prevent the future buildup of sclerotic material.
- One complication with delivery of drug coated balloons is that the drug coating can rub off the balloon. This can occur primarily in two scenarios—first, when the drug coated balloon is initially placed through the hemostasis valve of the guiding sheath for entry into the guiding sheath (where most of the drug loss typically takes place). Second, when the drug coated balloon is being pushed through the guiding sheath. This drug loss is due to contact friction between the balloon and, respectively, the hemostasis valve and the inner surface of the guiding sheath. Drug loss during placement and tracking can limit the amount of drug that is available to treat the stenosis and can enhance the chance of continued stenosis or restenosis since less drug is available to treat the problem region.
- This is particularly problematic in larger arteries, such as the superficial femoral and popliteal arteries, since the stenotic regions can become particularly large and calcified due to the relatively larger vessel size and therefore may need a large drug dose to treat the target region. Drug loss is therefore a significant problem associated with the use of drug coated balloons.
- Embodiments herein include protective sleeves designed to help protect the drug coated balloon during placement within the hemostasis valve of the guiding sheath as well as during tracking through the larger guiding sheath. For the purposes of the figures discussed in the description, unless noted otherwise anything on the left is considered “distal” or in the direction of the patient body/vasculature, while anything on the right is considered proximal or in the direction outside of the patient body/vasculature.
-
FIG. 1a shows a typical drug-coatedballoon catheter 103 having an inflatable drug-coatedballoon 102 mounted on the distal end of thecatheter 103 and in which a portion of the balloon has adrug coating 102A. Preferably, substantially all of the length and circumference of theballoon 102 includes thedrug coating 102A. Often, the proximal and distal tapered ends of theballoon 102 are free of the drug coating, since these portions are unlikely to contact the vessel. - The drug-coated
balloon catheter 103 includes anelongated body portion 106 having afirst lumen 106A located along all or a portion of the length of thebody portion 106 and through which aguidewire 108 can be advanced (and/or a contrast agent or therapeutic material can be delivered within the patient). Asecond inflation lumen 106B extends from a proximal end of thebody portion 106 to an opening within theballoon 102, allowing for delivery of inflation media during a procedure. - Balloon catheters also often include a separate
rapid exchange port 106C at some distal location along thebody portion 106 andlumen 106A to allow quicker placement and removal of theguidewire 108, as shown inFIG. 1a .Balloon catheters 103 are typically placed into a hemostasis valve of a guiding sheath and then are delivered through the guiding sheath for delivery to a target treatment area, however, as discussed above, there is significant drug loss associated with these steps. -
FIG. 1b illustrates aprotective sleeve 100 according to one embodiment to protect the drug-coatedballoon 102 of the drug-coatedballoon catheter 103 during placement through the hemostasis valve of the guiding sheath and passage through the guiding sheath. Theprotective sleeve 100 includes a distaltubular section 101 and aproximal body portion 105 having an arc-shaped channel or “half-pipe” shapedregion 105A that extends to the proximal end of thebody portion 105 that forms anopening 104 to the distaltubular section 101. - As best seen in
FIG. 1c , theballoon 102 is advanced within the distaltubular section 101, since both theproximal aperture 104 and internal diameter of thesection 101 are larger than the deflated diameter of theballoon 102. Thebody portion 106 of thecatheter 103 can be positioned within the non-tubular arc-shapedregion 105A. Preferably, theprotective sleeve 100 is placed over thecatheter 103, with the balloon already inside of the distaltubular section 101 prior to placement within thehemostasis valve 112 of guidingsheath 110 and is then pushed through guidingsheath 110—as shown inFIG. 2 . -
Protective sleeve 100 provides an intermediate surface to protect the balloon from direct contact with thehemostasis valve 112 when the drug-coatedballoon 102 enters the guidingsheath 110, as well as an intermediate surface to protect the drug-coatedballoon 102 from direct contact with the inner diameter of the guiding sheath when tracked through said guidingsheath 110. Drug loss primarily occurs during placement through the hemostasis valve 112 (due to the reduced diameter of the hemostasis valve, as well as the rough texture of the hemostasis valve) and secondarily during tracking through the guidingsheath 110. Theprotective sleeve 100 reduces or eliminates these problems by protecting the drug-coatedballoon 102 when it enters thehemostasis valve 112 and during tracking through the guidingsheath 110. Theprotective sleeve 100 should be sized to fit within the inner diameter of the guidingsheath 110 so it can be advanced through the guidingsheath 110. The external surface of the balloonprotective sleeve 100 can utilize a hydrophilic or other friction-reducing coating to reduce friction with theexternal guiding sheath 110. The balloonprotective sleeve 100 may also be made of a lubricious polymer to reduce friction between theoverlying guiding sheath 110 and underlyingprotective sleeve 100. - The
protective sleeve 100 is advanced by the physician at its proximal end to so as to also advance theenclosed balloon catheter 103 through guidingsheath 110. As previously discussed, theproximal section 105 of theprotective sleeve 100 is not a fully enclosed tube likedistal section 101, but rather an arc-shaped or “half-pipe” shapedregion 105A. This configuration increases the ease of loading the drug coatedballoon 102 since theballoon 102 must only be pushed through cut-outaperture 104 to access the distaltubular section 101 instead of being pushed through the entire length of the balloonprotective sleeve 100, which would be the case if the entire length of the balloonprotective sleeve 100 had a completely enclosed tubular shape. Since thebody portion 106 resides in the arc-shapedportion 105A of theprotective sleeve 100, the physician can advance both thesleeve 100 and thecatheter 103 together by manipulating only the proximal end of the proximal body portion 105 (or optionally both proximal ends of theproximal body portion 105 and the catheter 103). In this way, theproximal body portion 105 can be thought of as a navigational section since a user grips the proximal part ofproximal body portion 105 to moveprotective sleeve 100 along with theenclosed balloon catheter 103 and drug coatedballoon 102. - After passing through guiding
sheath 110 and being placed at the target treatment site, the drug coatedballoon 102 is exposed in one of a few ways. First, theprotective sleeve 100 is pushed out from the guidingsheath 110 or the guidingsheath 110 is proximally withdrawn to expose the distaltubular section 101 ofprotective sleeve 100. Then, theprotective sleeve 100 is retracted to expose drug coatedballoon 102, the balloon catheter is pushed out from theprotective sleeve 100, or both techniques can be performed together (in a dual push/pull method). Since the drug-coatedballoon 102 is located within theprotective sleeve 100, a small amount of drug loss due to friction between the drug-coatedballoon 102 and theprotective sleeve 100 may be possible, however this drug loss is much less than the amount that would otherwise occur without thesleeve 100. To further mitigate drug loss from theballoon 102, the inner surface ofprotective sleeve 100 may include a hydrophilic or otherwise friction-reducing coating, or be made of a lubricious polymer. - The distal end of the distal
tubular section 101 may further include a radiopaque (e.g. tantalum)marker band 114, as seen inFIG. 3a . Guidingsheaths 110 often include a marker band at about 3 cm from the distal tip so that a device delivered through the guiding sheath can be aligned with the distal tip to ensure proper placement relative to the guidingsheath 110. In this respect, themarker band 114, when aligned with the marker band of guidingsheath 110, helps the user ascertain that the protective sleeve is at the distal end of the guiding sheath. - The
aperture 104 created between the distaltubular region 101 and thechannel 105A can be formed from a generally perpendicular wall cut (i.e., a cut perpendicular to the elongated axis of thesleeve 100, as seen inFIG. 1b , or can be cut at an angle that decreases in the proximal direction, as seen inFIG. 3b (e.g., 45 degrees or an angle less than 90 degrees) to create a transition between the tworegions protective sleeve 100 can be manufactured by cutting a portion of a tube between theaperture 104 and the proximal end of theproximal section 105, thereby forming the arc-shaped orchannel portion 105A. In another example, a distaltubular section 101 can be connected to an entire tube cut lengthwise to form theproximal portion 105. - Drug coated balloons are often pleated, as shown in
FIG. 4 , to reduce the amount of drug that can potentially be lost. Thepleat 116 includes anouter region 116A which may contact the surface overlying theballoon 102 and aninner region 116B which is protected from the overlying surface. This pleated design helps ensure the entire surface of the balloon is not exposed and thereby limits the amount of drug that is lost during placement and tracking. - The drug coated
balloon 102, as discussed earlier, includes alumen 106A that accommodates aguidewire 108, shown inFIG. 1A , and provides a path for any subsequently introduced therapeutic materials that may be used in the treatment area. The proximal end ofballoon 102 is connected to an inflation lumen 1066 to allow inflation media (e.g. liquid contrast agent) to be injected through a port in thecatheter body 106 to inflate theballoon 102 once deployed in the target treatment site in the vasculature. -
FIG. 5 shows the balloon and balloonprotective sleeve 100 being placed within thehemostasis valve 112 of guidingsheath 110, for tracking through said guidingsheath 110. Various embodiments are contemplated regarding the placing of balloon withinprotective sleeve 100. In one embodiment, theballoon 102 is preplaced within distaltubular section 101 ofprotective sleeve 100 and sold as a package to the end user. In another embodiment, the end user physically places theballoon 102 within distaltubular section 101 ofprotective sleeve 100, for example by pushing theballoon 102 throughaperture 104 ofprotective sleeve 100. Once the balloon is within theprotective sleeve 100, theprotective sleeve 100 is physically placed within thehemostasis valve 112 and pushed through guidingsheath 110 in the manner described earlier. Please note, in the embodiment where the end user would place the balloon within the distaltubular section 101 ofprotective sleeve 100, theballoon 102 may need to be placed within a temporary protective structure to prevent drug loss during the storage and shipping process—this temporary protective structure would then be removed by the end user when said user places the balloon within the distaltubular section 101 ofprotective sleeve 100. - Other embodiments of the
protective sleeve 100 can forego cut-outregion 105A and instead is entirely tubular. With this embodiment, it would be beneficial for theprotective sleeve 100 to be sold/delivered pre-loaded with the drug coatedballoon 102 to the end-user to minimize the effort needed to track the balloon through a fully tubular protective structure. - The earlier discussion highlighted placement of a drug-coated
balloon 102 within a guidingsheath 110, as well as tracking theballoon 102 through the guidingsheath 110, as the primary scenarios where drug loss can occur. However, exposure to blood can also cause drug loss from the drug coatedballoon 102. Generally, once the drug-coatedballoon 102 is tracked to the distal end of the guidingsheath 110, the distal part of the drug-coatedballoon 102 may contact blood even before theballoon 102 is deployed, and the pressurized flow of blood may cause of thedrug coating 102A to be removed from theballoon 102. Theprotective sleeve 100 can address some of these issues by limiting the amount of balloon surface which the blood can contact due to the surface area of theprotective sleeve 100. However theprotective sleeve 100 alone may not entirely prevent drug loss due to blood contact.FIGS. 6-8 describe various embodiments to reduce this drug loss due to blood contact/blood flow. - In
FIG. 6 , anose cone 118 is attached to the distal end ofcatheter body 106, past the distal end ofballoon 102 that helps block or redirect direct blood flow contact with theballoon 102, thereby further reducing loss of thedrug coating 102A. Thenose cone 118 is either disposed around thecatheter body 106 or includes a passage through it that is aligned with thelumen 106A, such that thenose cone 118 provides an outlet for a guidewire or other agents advanced through thelumen 106A. Preferably, thenose cone 118 can be a proximally-increasing conical shape as pictured or similar ramped shape so that the proximal end of the cone has the greatest thickness to prevent blood from prematurely contacting the balloon during delivery, while the distal end has a smaller profile in order to not materially impede blood flow once the balloon is placed within the vasculature. However, a variety of shapes are contemplated including cones, cylinders, elliptical, ovular, and/or bullet-like shapes. - In one embodiment, the
nose cone 118 is located within the balloonprotective sleeve 110 and the proximal end of thenose cone 118 has a diameter similar to the inner diameter of the balloonprotective sleeve 100, thereby preventing blood from contacting the drug-coatedballoon 102. In another embodiment, thenose cone 118 is located distal to balloonprotective sleeve 110 and the proximal end ofnose cone 118 is has a diameter similar to the inner diameter of guidingsheath 110. - Blood-induced drug coating loss can also be addressed by narrowing the distal end of the balloon protective sleeve so that there is less available space for the blood to contact the drug-coated
balloon 102.FIGS. 7-8 illustrate one such embodiment, in which a balloonprotective sleeve 200 has a diametrically narroweddistal section 220 relative to the proximal portion of the distaltubular section 201. The narroweddistal section 220 accommodates all of theballoon 102 or solely the distal part of the balloon as theballoon 102 is being housed within the protective sleeve while tracking through the guidingsheath 110. Narroweddistal section 220 has a smaller diameter compared to the rest of the distal tubular section 201 (which accommodates the balloon 102) ofprotective sleeve 200 and therefore sits tighter relative to the balloon, limiting the space for blood to enter. This mitigates the chance that blood can enter and remove thedrug coating 102A from theballoon 102. - Narrowed
distal section 220 shown inFIGS. 7-8 can be used instead of thenose cone 118 shown inFIG. 6 , or can be used along with nose-cone 118 to provide multiple levels of protection to help prevent blood from pushing or washing thedrug coating 102A off of the balloon. - Various embodiments of the narrowed
distal section 220 embodiment are contemplated. For instance, the entire section that the drug-coatedballoon 102 is located within can be relatively narrow. Alternatively, just a distal part is narrowed such that a proximal section of theballoon 102 is located in an enlarged proximal section while the distal section of the balloon is located within a narrowedsection 220. - An alternative embodiment utilizing the narrowed
distal section 220 described above can utilize a fuller distal section that the balloon sits within (sized similar totubular section 101 inFIGS. 1-2 ), then a smaller narroweddistal section 220 beyond this balloon, where the narrowed section would limit the amount of blood that could enter the protective sleeve and contact the drug coatedballoon 102. - The earlier description discussed how the balloon catheter 103 (of which drug coated
balloon 102 is a part), is tracked through guidingsheath 110 by pushing/pulling the proximal end of theprotective sleeve 100, which in turn conveys the balloon catheter 100 (and drug coated balloon 102) since the balloon catheter is contained withinprotective sleeve 100. Theproximal section 105 of theprotective sleeve 100 is not tubular in several of the embodiments to ease placement of the drug coatedballoon 102 within theprotective sleeve 100. However, one drawback to this arrangement is that since theproximal part 105 of theprotective sleeve 100 is cut-away to form achannel 105A, there is less axial strength or kink resistance to theprotective sleeve 100 due to the smaller cross-sectional area. - In
FIGS. 7-8 , theproximal section 205 of the protective sleeve has a greater curvature to the arc of itschannel 205A compared to thechannel 105A shown in the embodiment ofFIGS. 1-3 b, which is accomplished by making a more scalloped cut at region 204 (i.e., a cut of increased circumference/width) to define the entry point for the drug coated balloon. This scalloped cut is defined by a divot or inward taperedcut region 204 a which creates enough of a gap, entry, space, or port to accommodate the drug coatedballoon 102 within the distally placedtubular section 201, which may not otherwise fit due to the relativelynarrow channel 105A opening. Thisproximal section 105 with a smaller opening of thechannel 205A may be used in any of the protective sleeve embodiments to augment the push strength of the protective sleeve. - The primary locations in which loss of the drug coating can occur when tracking a drug coated balloon through a guiding sheath, as discussed earlier, are during placement within a
hemostasis valve 112 of a guidingsheath 110 as well as during tracking through the guidingsheath 110—where thehemostasis valve 112 is the location where the greatest amount ofdrug coating 102A is lost. Loss ofdrug coating 102A occurs due during placement through thehemostasis valve 112 for a few reasons. First, the smaller diameter of thehemostasis valve 112 compared to the guiding sheath diameter causes increased contact friction with theballoon 102 when theballoon 102 is placed through thehemostasis valve 112. Second, the hemostasis valve port is not smooth which can promote loss ofdrug coating 102A due to friction. Third, drug-coatedballoons 102 are fairly soft, meaning the physician generally must grip theballoon 102 to propel it through thehemostasis valve 112, which causes loss of the drug coating due to touch. Finally, retrograde blood flow through thehemostasis valve 112 can also cause drug loss due to contact with blood. The following embodiments are directed to a relatively shorter protective sleeve that functions solely to protect the drug coatedballoon 102 when its inserted into thehemostasis valve 112—which is the primary scenario where blood loss occurs, but does necessarily not protect theballoon 102 while it is tracked through the guidingsheath 110. -
FIG. 9 illustrates a shortenedprotective sleeve 300 which can also be considered aninsertion sleeve 300 since the function of the sleeve is to protect the drug-coatedballoon 102 solely during insertion through thehemostasis valve 112 of a guidingsheath 110. Sinceprotective sleeve 300 only protects the balloon during insertion into thehemostasis valve 112 it can be much shorter thanprotective sleeve embodiments FIGS. 1-8 which must span the complete length of the guidingsheath 110. - The
protective sleeve 300 can be placed over theballoon 102 when theballoon 102 is placed inside thehemostasis valve 112 of guidingsheath 110 to protect the drug-coated balloon from drug loss when being placed within saidhemostasis valve 112. Theprotective sleeve 300 has athin cut 301 extending along its entire length (e.g. a cut 301 a defining an opening that is 0.002 inches or less), forming a cross-sectional c-shape instead of a completely oval/circular shape. One end ofprotective sleeve 300 is preferably flared or radially opened to form a flared end 305 (i.e., thecut 301A increases in width in the proximal direction). In one example, theprotective sleeve 300 is formed as a cylinder but thecut 301A insection 305 is larger thancut 301 in the rest of the sleeve causing flaredend 305 to adopt its flared shape—meaning the larger shape of the flared end is due to the larger cut used inregion 305. As shown inFIG. 9 , cut 301A is tapered such that the cut size inend section 301C is larger than the cut size insection 301B. In one example, the cut-size inend section 301C defines an opening of about 0.17 inches to about 0.23 inches. Theprotective sleeve 300 is about 2.75-3.25 inches in length and the flared end is about 0.5 to 1 inch in length. In another example,protective sleeve 300 is about 3 inches, about 7.62 centimeters, or about 8 centimeters in length and flaredend 305 is about 0.75 inches in length.Protective sleeve 300 can be formed from a variety of materials including a polymeric material such as Pebax 7233 SA01. In one example,protective sleeve 300 has an inner diameter of about 0.1 inches and an outer diameter of about 0.115 inches. Sinceprotective sleeve 300 is generally formed from a cylinder which is given a larger cut inregion 301C to adopt the flaredend 305 as described earlier, the protective sleeve diameter can be thought of as the outer diameter of the sleeve plus the size of the cut. Using this approach, the protective sleeve's flaredend 305 diameter is about 0.285 inches to 0.345 inches, or about 0.315 inches—while the protective sleeve's diameter in the non-flared portion of the sleeve is about 0.115 inches to 0.12 inches, or about 0.117 inches. -
FIG. 10 shows an embodiment in which theprotective sleeve 300 is pre-placed on the proximal part of theballoon catheter 103, where theballoon catheter 100 is sold to the end user with theprotective sleeve 300 already located on the proximal part of saidballoon catheter 100. The proximal end of protective sleeve 300 (which coincides with flared end 305) would sit over theenlarged strain relief 303 of theballoon catheter 103. -
Proximal flare 305 is useful for a couple purposes. First, the flare provides a slightly enlarged region to better fit overstrain relief 303. Second, theproximal flare 305 provides a smoother entry for the drug coated balloon when said balloon is loaded through saidprotective sleeve 300. ComparingFIG. 9 andFIG. 10 , cut 301 would sit on the bottom ofprotective sleeve 300 shown inFIG. 10 . The user can simply removeprotective sleeve 300 from theballoon catheter 103, and then place theprotective sleeve 300 within the hemostasis valve of the guiding sheath—in a manner that will be explained in more detail below. - The method of using
protective sleeve 300 is shown inFIGS. 11-13 . Please note, as pertains to the figures anything on the left side would be considered distal and anything on the right side would be considered proximal.Protective sleeve 300 is first removed from the proximal section ofballoon catheter 103 so that the distal section of saidballoon catheter 103 is later be placed through saidprotective sleeve 300. Due to the presence of thecut 301, this removal can occur by applying force against the cut 301 (referring toFIG. 10 , one pulls upwards to removesleeve 300 sincecut 301 is located on the bottom of the sleeve 300). - Generally, drug coated balloons come pre-shipped in a
protective tube 307 during shipping and handling to protect the drug after manufacture. Thisprotective tube 307 must be removed prior to using the drug coated balloon/balloon catheter, prior to placement within the hemostasis valve of the guiding sheath. The distal part of the balloon catheter, which includes the drug coated balloon which is located at the distal end of theballoon catheter 103 aroundballoon catheter lumen 103 is shown inFIG. 11 . The distal part of the balloon catheter including surroundingprotective tube 307 is inserted through theprotective sleeve 300, so that the distal part of the balloon catheter and distal part ofprotective tube 307 sits past the distal end ofprotective sleeve 300.Protective tube 307 is then pulled distally (to the left) as shown inFIG. 12 to remove theprotective tube 300 from theballoon 102. After this, as shown inFIG. 13 , theprotective sleeve 300 is then placed within thehemostasis valve 112 of guidingsheath 110 so that theprotective sleeve 300 is positioned through theentire hemostasis valve 112. The balloon catheter is then pushed distally (in a leftward direction) to propel theballoon 102 through thehemostasis valve 112 and into the guidingsheath 110. Once theentire balloon 102 is past thehemostasis valve 112 and is loaded into the guiding sheath, theprotective sleeve 300 is proximally retracted (pulled to the right) and removed (e.g. by pulling against the cut, so pulling upwards inFIG. 13 to remove the entire sleeve 300) and the rest of theballoon catheter 103 is pushed through thehemostasis valve 112 and into the guidingsheath 110. - Alternative embodiments have a shortened
protective sleeve 300 as a separate element that is unconnected toballoon catheter 103; however pre-placement onballoon catheter 103 would provide a more convenient format to locate the shortenedprotective sleeve 300 as part of a balloon catheter system or kit. Alternative embodiments may also utilize a pre-scored or pre-weakened region in place ofcut 301, in which the user applies enough pressure to tearopen region 301. - The primary benefit of insertion sleeve/
protective sleeve 300 is that it protects the drug coatedballoon 102 from contact with the reduced diameter and roughened area of thehemostasis valve 112, thus mitigating the issue of drug loss during placement through saidhemostasis valve 112. One additional advantage of thecut section 301 of theprotective sleeve 300 is that when the sleeve is placed into a small-diameter tube, the ends of the tube can overlap to fit the smaller profile. Since thehemostasis valve 112 has a reduced diameter compared to the rest of the guiding sheath, theprotective sleeve 300 can curl over itself to fit this reduced diameter (meaning theprotective sleeve 300 can conform to fit a much smaller diameter hemostasis valve—by contrast, a non-cut tube could not fit into a hemostasis valve with a smaller diameter than the tube for obvious reasons). The earlier description discussed one cause of drug loss being exposure to blood. The ability of theprotective sleeve 300 to contract to fit thehemostasis valve 300 means there is less exposed surface area of the drug coated balloon available exposed to blood, further minimizing the chance of drug falling off the balloon during placement. - In the protective sleeve embodiments of
FIGS. 1-8 in which the protective sleeve extends the length of the guiding sheath and includes a distal tubular section to support the drug coated balloon, the sleeves must be relatively long since they are positioned within the guidingsheath 110. The distaltubular sections tubular sections protective sleeve 300 is that it is relatively short since it only must be large enough to spanhemostasis valve 112 of the guiding sheath. In some examples, as discussed earlier, theprotective sleeve 300 is about 3 inches, 7.62 centimeters, or about 8 centimeters in length. - When sclerotic material builds up in a vessel, it often adopts awkward shapes—as shown in the vessel cross section shown in
FIG. 14 in whichvessel 400 hassclerotic material 402 which leaves a smallervessel cross section 404 for blood flow. The sclerotic buildup narrows the space that blood can flow through the vessel, diminishing blood flow through the vessel in a phenomenon called stenosis—which can cause a variety of complications. Typical treatment procedures can proceed in a couple ways. One treatment option uses a high-pressure balloon to inflate and compress the sclerosis to try to restore regular blood flow to the vessel. However, if the sclerosis is particularly dense or if stenosis keeps recurring (a phenomenon known as restenosis), this method is not useful. - A second treatment option is to use a drug-coated balloon to apply drug to the vessel wall and sclerotic material to try to treat the stenosis. However, the irregular profile of the sclerotic material can make it difficult to effectively apply the drug equally around the vessel since it would be difficult for the balloon to adopt the awkward shape to conform to
vessel cross-section 404—in fact, inserting a drug coated balloon by itself would result in the drug-coated balloon only touching the “narrowest” part of the sclerotic region which is a very inefficient way to deliver the drugs. Additionally, the presence of a thick sclerotic layer would make it difficult for the drug to reach the wall of the blood vessel. Physicians often use a pre-dilation step to address this problem, where a first high-pressure balloon is inserted into the sclerotic region and expanded in order to compress the sclerosis and produce a consistent circular lumen—once there is a consistent circular lumen, it is much easier for the drug coated balloon to adopt a circular shape to treat the area. Once the pre-dilation step is completed a second balloon—a drug coated balloon which can be coated with anti-sclerotic drug such as Paclitaxel, Sirolimus, and/or Zotarolimus is then inserted and inflated to contact the sclerosis and vessel wall, and deliver drugs to said sclerosis and tissue. This procedure can take a substantial amount of time since a first balloon must be tracked through a guiding sheath and delivered to the target site and inflated for the pre-dilation step and then be deflated and withdrawn through the guiding sheath. Then a drug-coated balloon must be tracked through the guiding sheath and placed at the target site, expanded to deliver the drug, and then removed and withdrawn. The extra-step of pre-dilation takes extra time and can increase the risk of complications such as stroke in circumstances where there is significant narrowing of the blood vessels due to sclerosis. The following embodiments deal with a dual-balloon microcatheter system which includes both a dilation balloon and a compliant drug-coated balloon so that the dilation and drug delivery can take place simultaneously. -
FIG. 15 illustrates aballoon catheter system 405 having two balloons. The two-balloon system utilizes an outer, primary, highly-compliant drug coatedballoon 406 and an inner, secondary, high-pressure balloon 408. The inclusion of two balloons on one balloon catheter eliminates the need for a separate pre-dilation step since the inner balloon can dilate the vessel while the outer balloon can then conform to the stenosis after dilation and therefore there is no need for two separate balloon catheters and the time associated with tracking two separate balloon catheters through the vasculature to treat the stenosis. - In one embodiment, the two balloons are concentric, as is shown in
FIG. 15 . The balloon catheter contains two inflation lumens, one (408 a) to inflate the inner balloon and the other (408 b) to inflate the outer balloon—while athird lumen 410 provides access for a guidewire or additional therapeutic materials. Typical inflation media such as liquid contrast agent can be used to inflate the balloons. The inner balloon is a high-pressure balloon and should be high strength in order compress the sclerosis, thereby dilating the vessel. Conventional high-pressure balloon material such as nylon can be used for this inner/secondary balloon 408. Theouter balloon 406 is highly conformable and is meant to conform to the shape of the sclerotic region in order to ensure even drug delivery throughout the entire sclerotic region. Soft, compliant material is therefore ideal for the inner/primary balloon; Polyblend 18-45 may be used for the inner/primary balloon. - The method of use of the dual-
balloon catheter system 406 to treat a sclerotic region like the one shown inFIG. 14 is described, as follows. The primary, compliant outer drug-coatedballoon 406 is first inflated and due to the compliant nature of the balloon, this balloon can generally conform to the shape of the sclerotic region to deliver drug to the region—however depending on the nature of the stenotic shape it may not completely comply with the shape if the shape is particularly complex or irregular. The physician can observe the treatment site through fluoroscopy to determine how well the compliant, drug-coated balloon conforms to the vessel shape. If dilation is needed to get a consistent, circular shape or to compress the sclerosis, then the primary,outer balloon 406 is deflated and the secondary, inner high-pressure balloon 408 is then inflated. Since theouter balloon 406 is located over theinner balloon 408, theouter balloon 406 maintains contact with the sclerosis, but the force from the inner-high pressure balloon further compresses the sclerosis and creates a consistent, open lumen for blood flow through the vessel. Note that even if outer drug-coatedballoon 406 is complying to the stenosis shape, it may still be desirable to use a dilation procedure to decrease the amount of stenosis buildup and “open” up the vessel for blood flow—the inclusion of the high pressureinner balloon 408 allows this to be done while utilizing the same balloon catheter. - Other double balloon systems are additionally contemplated. For instance, a dual lumen inflation system can be used with two balloons where the balloons are positioned longitudinally adjacent with respect to each other (i.e., proximally/distally of each other). One balloon is a compliant drug-coated balloon, and a second linearly displaced balloon is a high-pressure balloon. With this system, the balloons can be used in either order (e.g. either the compliant, drug-coated balloon or the high-pressure balloon could be inflated and used first). The catheter can be linearly moved so that either the first balloon or the second balloon is aligned with the sclerotic region.
- Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.
Claims (21)
1-17. (canceled)
18. A balloon catheter adapted for insertion into a hemostasis valve of a guide catheter comprising:
a slit sleeve configured to be positioned within the hemostasis valve of the guide catheter;
a drug coated balloon of the balloon catheter configured to be inserted through the slit sleeve positioned within the hemostasis valve of the guide catheter;
a longitudinal opening extending along an entire length of only a side of the slit sleeve;
the slit sleeve forming a generally tubular shape and having a first non-flared section in which the longitudinal opening has a first width, and a second flared end section in which the longitudinal opening has a second width that is larger than the first width and increases in width in a direction away from the first non-flared section;
wherein the first width of the longitudinal opening in the first non-flared section of the slit sleeve is about 0.002 inch.
19. The balloon catheter of claim 18 , wherein the drug-coated balloon is coated with one of Paclitaxel, Sirolimus, or Zotarolimus.
20. The balloon catheter of claim 18 , wherein the second width of the longitudinal opening in the second flared end section of the slit sleeve is tapered and has a maximum opening size of 0.17 inches to 0.23 inches.
21. The balloon catheter of claim 18 , wherein the second flared end section of the slit sleeve has a diameter of 0.285 inches to 0.345 inches.
22. The balloon catheter of claim 18 , wherein the first non-flared section of the slit sleeve has a diameter of 0.115 inches to 0.12 inches.
23. The balloon catheter of claim 18 , wherein the second flared end section of the slit sleeve has a length of 0.5 inches to 1 inch.
24. The balloon catheter of claim 18 , wherein the slit sleeve has a length of 2.75 inches to 3.75 inches.
25. The balloon catheter of claim 18 , wherein the slit sleeve is composed of a polymeric material.
26. The balloon catheter of claim 18 , wherein the second flared end section of the slit sleeve sits over a strain relief of the balloon catheter.
27. The balloon catheter of claim 18 , further comprising a protective tube over the drug coated balloon.
28. The balloon catheter of claim 27 , wherein the slit sleeve is sized to fit over the protective tube, to aid in removing the protective tube prior to inserting the drug coated balloon through the hemostasis valve of the guiding sheath.
29. The balloon catheter of claim 27 , wherein the slit sleeve has a larger diameter than that of the protective tube.
30. A system for loading a drug coated balloon of a balloon catheter into a hemostasis valve of a guide catheter to minimize drug loss from the drug coated balloon comprising:
a slit sleeve configured to be positioned within the hemostasis valve of the guide catheter;
the drug coated balloon of the balloon catheter configured to be inserted through the slit sleeve positioned within the hemostasis valve of the guide catheter;
a longitudinal opening extending along an entire length of only a side of the slit sleeve;
the slit sleeve forming a generally tubular shape and having a first non-flared section in which the longitudinal opening has a first width, and a second flared end section in which the longitudinal opening has a second width that is larger than the first width and increases in width in a direction away from the first non-flared section;
wherein the first width of the longitudinal opening in the first non-flared section of the slit sleeve is about 0.002 inch.
31. The system of claim 30 , wherein the second flared end section of the slit sleeve has a diameter of 0.285 inches to 0.345 inches.
32. The system of claim 30 , wherein the first non-flared section of the slit sleeve has a diameter of 0.115 inches to 0.12 inches.
33. The system of claim 30 , wherein the second flared end section of the slit sleeve has a length of 0.5 inches to 1 inch.
34. The system of claim 30 , wherein the slit sleeve has a length of 2.75 inches to 3.75 inches.
35. A drug coated balloon adapted for insertion into a hemostasis valve of a guide catheter comprising:
a slit sleeve configured to be positioned within the hemostasis valve of the guide catheter;
the drug coated balloon configured to be inserted through the slit sleeve positioned within the hemostasis valve of the guide catheter;
a longitudinal opening extending along an entire length of only a side of the slit sleeve;
the slit sleeve forming a generally tubular shape and having a first non-flared section in which the longitudinal opening has a first width, and a second flared end section in which the longitudinal opening has a second width that is larger than the first width and increases in width in a direction away from the first non-flared section;
wherein the first width of the longitudinal opening in the first non-flared section of the slit sleeve is about 0.002 inch.
36. The drug coated balloon of claim 35 , wherein the second flared end section of the slit sleeve has a diameter of 0.285 inches to 0.345 inches.
37. The drug coated balloon of claim 35 , wherein the slit sleeve has a length of 2.75 inches to 3.75 inches.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/914,178 US20200368501A1 (en) | 2016-10-05 | 2020-06-26 | Balloon Catheter Systems |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404647P | 2016-10-05 | 2016-10-05 | |
US201662414520P | 2016-10-28 | 2016-10-28 | |
US15/726,264 US10874826B2 (en) | 2016-10-05 | 2017-10-05 | Balloon catheter systems |
US16/914,178 US20200368501A1 (en) | 2016-10-05 | 2020-06-26 | Balloon Catheter Systems |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/726,264 Continuation US10874826B2 (en) | 2016-10-05 | 2017-10-05 | Balloon catheter systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200368501A1 true US20200368501A1 (en) | 2020-11-26 |
Family
ID=61757531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/726,264 Active 2038-02-13 US10874826B2 (en) | 2016-10-05 | 2017-10-05 | Balloon catheter systems |
US16/914,178 Pending US20200368501A1 (en) | 2016-10-05 | 2020-06-26 | Balloon Catheter Systems |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/726,264 Active 2038-02-13 US10874826B2 (en) | 2016-10-05 | 2017-10-05 | Balloon catheter systems |
Country Status (5)
Country | Link |
---|---|
US (2) | US10874826B2 (en) |
EP (2) | EP3522824B1 (en) |
JP (1) | JP7048592B2 (en) |
CN (1) | CN110177522B (en) |
WO (1) | WO2018067875A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113195033A (en) * | 2019-03-22 | 2021-07-30 | 泰尔茂株式会社 | Balloon catheter and balloon deployment method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020116045A1 (en) * | 2001-02-22 | 2002-08-22 | Eidenschink Tracee E.J. | Crimpable balloon/stent protector |
US20040093005A1 (en) * | 2002-09-30 | 2004-05-13 | Durcan Jonathan P. | Protective sleeve assembly for a balloon catheter |
US20100249490A1 (en) * | 2009-03-27 | 2010-09-30 | Circulite, Inc. | Transseptal cannula device, coaxial balloon delivery device, and methods of using the same |
US20100268123A1 (en) * | 2009-04-16 | 2010-10-21 | Tyco Healthcare Group Lp | IUPC Introducer |
US20120296313A1 (en) * | 2011-05-20 | 2012-11-22 | Abbott Cardiovascular Systems Inc. | Drug Coated Balloon Hemostatic Valve Insertion/Balloon Sheath |
US20160058983A1 (en) * | 2013-05-03 | 2016-03-03 | C.R. Bard, Inc. | Peelable Protective Sheath |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147302A (en) * | 1989-04-21 | 1992-09-15 | Scimed Life Systems, Inc. | Method of shaping a balloon of a balloon catheter |
US5242399A (en) | 1990-04-25 | 1993-09-07 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5634901A (en) | 1992-11-02 | 1997-06-03 | Localmed, Inc. | Method of using a catheter sleeve |
US5800517A (en) * | 1996-08-19 | 1998-09-01 | Scimed Life Systems, Inc. | Stent delivery system with storage sleeve |
US5843027A (en) | 1996-12-04 | 1998-12-01 | Cardiovascular Dynamics, Inc. | Balloon sheath |
US5893868A (en) | 1997-03-05 | 1999-04-13 | Scimed Life Systems, Inc. | Catheter with removable balloon protector and stent delivery system with removable stent protector |
US6152944A (en) * | 1997-03-05 | 2000-11-28 | Scimed Life Systems, Inc. | Catheter with removable balloon protector and stent delivery system with removable stent protector |
US6093173A (en) | 1998-09-09 | 2000-07-25 | Embol-X, Inc. | Introducer/dilator with balloon protection and methods of use |
US6110146A (en) * | 1998-09-30 | 2000-08-29 | Medtronic Ave, Inc. | Protector for catheter balloon with guidewire backloading system |
US8652198B2 (en) * | 2006-03-20 | 2014-02-18 | J.W. Medical Systems Ltd. | Apparatus and methods for deployment of linked prosthetic segments |
EP2262566A1 (en) | 2008-03-06 | 2010-12-22 | Boston Scientific Scimed, Inc. | Balloon catheter devices with folded balloons |
EP3159033B1 (en) * | 2008-05-01 | 2019-02-27 | Bayer Intellectual Property GmbH | Catheter balloon drug adherence techniques and methods |
GB0921240D0 (en) | 2009-12-03 | 2010-01-20 | Angiomed Ag | Stent device delivery system and method of making such |
EP2361651B1 (en) * | 2010-02-25 | 2016-04-27 | Biotronik AG | System comprising a protective sleeve and a medical device, and method for the production thereof |
US9272085B2 (en) * | 2010-08-03 | 2016-03-01 | Cook Medical Technologies Llc | Method of introducing a catheter |
CN104619375A (en) * | 2012-09-11 | 2015-05-13 | 波士顿科学西美德公司 | Loading tools for use with balloon catheters |
WO2015061801A2 (en) * | 2013-10-26 | 2015-04-30 | Accumed Radial Systems Llc | System, apparatus, and method for creating a lumen |
EP2995339B1 (en) * | 2014-09-15 | 2020-01-08 | Biotronik AG | Balloon catheter |
US9375336B1 (en) * | 2015-01-29 | 2016-06-28 | Intact Vascular, Inc. | Delivery device and method of delivery |
-
2017
- 2017-10-05 EP EP17859220.0A patent/EP3522824B1/en active Active
- 2017-10-05 JP JP2019518537A patent/JP7048592B2/en active Active
- 2017-10-05 CN CN201780075276.8A patent/CN110177522B/en active Active
- 2017-10-05 US US15/726,264 patent/US10874826B2/en active Active
- 2017-10-05 EP EP23192287.3A patent/EP4282385A3/en active Pending
- 2017-10-05 WO PCT/US2017/055422 patent/WO2018067875A1/en unknown
-
2020
- 2020-06-26 US US16/914,178 patent/US20200368501A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020116045A1 (en) * | 2001-02-22 | 2002-08-22 | Eidenschink Tracee E.J. | Crimpable balloon/stent protector |
US20040093005A1 (en) * | 2002-09-30 | 2004-05-13 | Durcan Jonathan P. | Protective sleeve assembly for a balloon catheter |
US20100249490A1 (en) * | 2009-03-27 | 2010-09-30 | Circulite, Inc. | Transseptal cannula device, coaxial balloon delivery device, and methods of using the same |
US20100268123A1 (en) * | 2009-04-16 | 2010-10-21 | Tyco Healthcare Group Lp | IUPC Introducer |
US20120296313A1 (en) * | 2011-05-20 | 2012-11-22 | Abbott Cardiovascular Systems Inc. | Drug Coated Balloon Hemostatic Valve Insertion/Balloon Sheath |
US20160058983A1 (en) * | 2013-05-03 | 2016-03-03 | C.R. Bard, Inc. | Peelable Protective Sheath |
Also Published As
Publication number | Publication date |
---|---|
JP2019528995A (en) | 2019-10-17 |
CN110177522B (en) | 2021-07-30 |
EP3522824B1 (en) | 2023-08-30 |
WO2018067875A1 (en) | 2018-04-12 |
EP3522824A4 (en) | 2020-07-15 |
EP4282385A3 (en) | 2024-02-28 |
US10874826B2 (en) | 2020-12-29 |
JP7048592B2 (en) | 2022-04-05 |
US20180093071A1 (en) | 2018-04-05 |
CN110177522A (en) | 2019-08-27 |
EP3522824A1 (en) | 2019-08-14 |
EP4282385A2 (en) | 2023-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11707605B2 (en) | Expandable sheath with longitudinally extending reinforcing members | |
EP3570784B1 (en) | Expandable sheath | |
US10398469B2 (en) | Expandable introducer sheath | |
US20170028170A1 (en) | Guide catheter extension device and methods of use for cardiology procedures | |
US10729454B2 (en) | Guidewire capture | |
US6375660B1 (en) | Stent delivery system with a fixed guide wire | |
US20060004439A1 (en) | Device and method for assisting in the implantation of a prosthetic valve | |
US8007490B2 (en) | Reduced width dual-lumen catheter | |
US20080161902A1 (en) | Delivery system and sheath for endoluminal prosthesis | |
US10953197B2 (en) | Guide extension catheter | |
JP6410743B2 (en) | Delivery device and delivery method | |
EP3082661B1 (en) | Balloon catheters and system | |
US20080006554A1 (en) | Packaging assembly for a catheter | |
US20020055733A1 (en) | Catheter assembly and method of use | |
US20170143355A1 (en) | Path Creation Through Occlusion | |
EP1772116A2 (en) | Stent delivery system using a steerable guide wire. | |
EP3826821B1 (en) | Methods of making an expandable sheath | |
US20200368501A1 (en) | Balloon Catheter Systems | |
US10456160B2 (en) | Stenotic region scoring assembly and method | |
AU6957900A (en) | Rapid exchange self-expanding stent delivery catheter system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |